Rifampin isoniazid pyrazinamide dosage and administration: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
RIFATER is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. | RIFATER is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. | ||
Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. | Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still [[sputum]] or culture positive, if resistant organisms are present, or if the patient is [[HIV]] positive. | ||
Concomitant administration of pyridoxine (B6) is recommended in the malnourished, in those predisposed to neuropathy (e.g., alcoholics and | Concomitant administration of [[pyridoxine]] (B6) is recommended in the malnourished, in those predisposed to [[neuropathy]] (e.g., alcoholics and [[diabetic]]s), and in adolescents. | ||
See Clinical Pharmacology, General, for dosing information in patients with renal failure. | See Clinical Pharmacology, General, for dosing information in patients with renal failure. | ||
| Line 26: | Line 26: | ||
The ratio of the drugs in RIFATER may not be appropriate in pediatric patients under the age of 15 (e.g., higher mg/kg doses of isoniazid are usually given in pediatric patients than adults).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFATER (RIFAMPIN, ISONIAZID AND PYRAZINAMIDE) TABLET, SUGAR COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=429a2f62-9fe6-4299-b314-92a9d22b1381 | publisher = | date = | accessdate }}</ref> | The ratio of the drugs in RIFATER may not be appropriate in pediatric patients under the age of 15 (e.g., higher mg/kg doses of isoniazid are usually given in pediatric patients than adults).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFATER (RIFAMPIN, ISONIAZID AND PYRAZINAMIDE) TABLET, SUGAR COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=429a2f62-9fe6-4299-b314-92a9d22b1381 | publisher = | date = | accessdate }}</ref> | ||
==References== | ==References== | ||
Revision as of 23:49, 3 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Dosage And Administration
RIFATER is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
Concomitant administration of pyridoxine (B6) is recommended in the malnourished, in those predisposed to neuropathy (e.g., alcoholics and diabetics), and in adolescents.
See Clinical Pharmacology, General, for dosing information in patients with renal failure.
Adults
Patients should be given the following single daily dose of RIFATER either 1 hour before or 2 hours after a meal with a full glass of water.
Patients weighing ≤44 kg – 4 tablets
Patients weighing between 45–54 kg – 5 tablets
Patients weighing ≥55 kg – 6 tablets
Pediatric Patients
The ratio of the drugs in RIFATER may not be appropriate in pediatric patients under the age of 15 (e.g., higher mg/kg doses of isoniazid are usually given in pediatric patients than adults).[1]
References
- ↑ "RIFATER (RIFAMPIN, ISONIAZID AND PYRAZINAMIDE) TABLET, SUGAR COATED [SANOFI-AVENTIS U.S. LLC]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.